BIOBEHAVIORAL STUDIES OF NARCOTICS ABUSE

麻醉品滥用的生物行为研究

• 批准号: 2012749
• 负责人: JACK H MENDELSON
• 金额: $ 10.02万
• 依托单位: MCLEAN HOSPITAL
• 依托单位国家: 美国
• 财政年份: 1979
• 资助国家: 美国
• 起止时间: 1979-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2012749
• 关键词: AIDS /HIV test; AIDS education /prevention; Macaca mulatta; behavioral /social science research tag; buprenorphine; cocaine; combination therapy; desensitization psychotherapy; detoxification; drug abuse therapy; drug screening /evaluation; group therapy; human subject; human therapy evaluation; longitudinal human study; mental health counseling; narcotics; oral administration; outpatient care; psychopharmacology; psychotherapy; questionnaires; self medication; social service; urinalysis; vocational guidance

Research protocols described in this competing renewal application for a Research Scientist Award (RSA DA0064) are based upon five research grants currently funded by NIDA and NIAAA. I am the Principal Investigator for assessment of Treatment Efficacy and AIDS Prevention (DA 06116) and a NIDA Clinical Research Center (DA 04059) for investigation of the biologic and behavioral concomitants of polydrug abuse in women. Currently I also am the Principal Investigator for a Postdoctoral Training Grant (DA 07252) supported by NIDA and a Principal Investigator or Co-Investigator for three additional research grants supported by NIDA and NIAAA. Our research programs, as well as our postdoctoral training activities, highlight multidisciplinary investigations of the causes and consequences of drug and alcohol abuse. NIDA supported research involves ongoing collaboration with scientists from the fields of neuroradiology and neuroimaging, neurology, reproductive endocrinology, pharmacology and public health. Current postdoctoral trainees who are participating in our NIDA supported program include individuals with specialized postdoctoral training in obstetrics and gynecology, reproductive endocrinology, neurology, psychiatry, veterinary medicine, neuroscience, analytical chemistry and public health. The clinical research program is concerned with assessment of the safety and effectiveness of new drugs for the treatment of concurrent opiate dependence and reduction of risk for HIV infection. We are conducting assessments of the safety and effectiveness of buprenorphine for the treatment of men with a long past history (average ten years) of intravenous heroin and cocaine dependence. Safety and effectiveness evaluations of buprenorphine are carried out on a Treatment Research Unit (TRU) which has been designed as a specialized Clinical Research Center for drug abuse treatment. We have also established an outpatient department which operates on a seven day basis throughout the year at the Massachusetts General Hospital. Both inpatient and outpatient treatment research units are staffed with specialists in internal medicine, clinical pharmacology, neurology, psychiatry and support staff with expertise in social, behavioral, legal and occupational counseling. Research supported by NIDA on Polydrug Abuse in Women involves both clinical and preclinical studies. This research also includes assessment of the effectiveness of new medications for the treatment of cocaine abuse and polydrug abuse in women and appropriate female primate models. Collaborative studies with scientists in the fields of reproductive endocrinology, obstetrics and gynecology and neuroradiology (including MRI and SPECT) are included in this research program.

此竞争续订应用程序中描述的研究协议 研究科学家奖（RSA DA0064）基于五项研究 NIDA和NIAAA目前资助的赠款。 我是校长 评估治疗功效和艾滋病预防的研究者（DA 06116）和NIDA临床研究中心（DA 04059）进行研究 女性滥用多药的生物学和行为伴随。 目前，我也是博士后的主要调查员 NIDA支持的培训补助金（DA 07252） 或为NIDA支持的另外三项研究赠款的共同投资者 和NIAAA。 我们的研究计划以及我们的博士后培训 活动，重点介绍有关原因和的多学科调查 毒品和酒精滥用的后果。 NIDA支持的研究涉及 与神经放射学领域的科学家进行的持续合作 以及神经影像学，神经学，生殖内分泌学，药理学和 公共卫生。 当前参加的博士后学员 我们的NIDA支持的计划包括具有专业的个人 postdoctoral training in obstetrics and gynecology, reproductive endocrinology, neurology, psychiatry, veterinary medicine, neuroscience, analytical chemistry and public health. The clinical research program is concerned with assessment of the safety and effectiveness of new drugs for the treatment of concurrent opiate dependence and reduction of risk for HIV infection. We are conducting assessments of the safety and effectiveness of buprenorphine for the treatment of men with a long past history (average ten years) of intravenous heroin and cocaine dependence. Safety and effectiveness evaluations of buprenorphine are carried out on a Treatment Research Unit (TRU) which has been designed as a specialized Clinical Research Center for drug abuse treatment. We have also established an outpatient department which operates on a seven day basis throughout the year at the Massachusetts General Hospital. Both inpatient and outpatient treatment research units are staffed with specialists in internal medicine, clinical pharmacology, neurology, psychiatry and support staff with expertise in social, behavioral, legal and occupational counseling. Research supported by NIDA on Polydrug Abuse in Women involves both clinical and preclinical studies. This research also includes assessment of the effectiveness of new medications for the treatment of cocaine abuse and polydrug abuse in women and appropriate female primate models. Collaborative studies with scientists in the fields of reproductive endocrinology, obstetrics and gynecology and neuroradiology (including MRI and SPECT) are included in this research program.